Search the Newsreel

How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Eli Lilly and Company will release its second-quarter earnings report before the opening bell on Wednesday, Aug. 5. Analysts expect the company to report quarterly earnings of …

Wise Ally Issues Profit Warning as Revenue Falls and Costs Surge

Eli Lilly: what the pharmaceutical company does and makes

Eli Lilly, founded in 1876, is a leading global pharmaceutical company headquartered in Indianapolis, known for its significant contributions to diabetes and obesity treatment. The company pioneered mass-produced insulin and now dominates the weight loss drug market with medications like Mounjaro and Zepbound, competing …

Bally's Marquette: A riverboat casino comes ashore

Bally's Marquette has transitioned from a riverboat casino to a permanent land-based facility, marking a new chapter in its history and for riverboat casinos in the US. The move was facilitated by a merger between Bally’s Corporation and Standard General, with construction on the …

Eli Lilly's Dominant Cardiometabolic Portfolio and Pipeline Support a Wide Moat

Eli Lilly's strong cardiometabolic portfolio and pipeline, alongside its innovative culture and significant financial commitment to drug development, are key drivers of its industry-leading growth potential. The company is launching several new blockbusters, and patent losses are becoming less of an issue, bolstering its …

Eli Lilly Stock Jumps Over 5% as Mounjaro Sales Surge 91%

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the drugmaker dominating the obesity and diabetes market, cranked up its 2026 revenue forecast after another monster quarter, sending the stock more than 5% higher in early U.S. trading. Management now expects annual revenue of …

Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy.

A few sectors have dominated the market this year, and healthcare isn’t one of them. Many stocks in the sector look ready to gain. Continue Reading

Lilly climbs, Novo falls as obesity drug battle intensifies

Eli Lilly's shares climbed while Novo Nordisk's dropped this week following their respective earnings reports, intensifying the battle for the lucrative GLP-1 obesity and diabetes treatment market. Novo Nordisk faced disappointment with its experimental CagriSema failing to match Lilly's tirzepatide in a trial and …

SpaceX, Alphabet, Nvidia, Micron, AMD, Uber, CVS, Lilly, and More Stocks That Explain Today’s Market

SpaceX stock sinks after earnings. AMD drops after Elon Musk says his AI and space company will exclusively use Nvidia chips. Continue Reading

CVS, Eli Lilly Forge Partnership on Improved GLP-1 Access; Companies Top Second-Quarter Views

CVS Health (CVS) is collaborating with Eli Lilly (LLY) as part of enhancements to its direct-to-cons PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

Ally Financial (ALLY) Posts Stronger Second Quarter Results, Is The Stock Still Cheap?

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress

Eli Lilly and Company reported strong second-quarter 2026 financial results, with revenue increasing 48% to $23.0 billion, driven primarily by Mounjaro and Zepbound. The company raised its full-year 2026 revenue guidance to $85.0 billion to $87.0 billion and updated its non-GAAP EPS guidance. Lilly …

Eli Lilly and Company Stock Analysis: Q2 Earnings Beat Meets Intraday Reversal

Eli Lilly and Company reported strong Q2 2026 earnings, driven by GLP-1 products, and raised full-year guidance. Despite this positive fundamental news, the stock experienced a sharp intraday reversal, closing significantly lower after an initial spike, forming a rejection candle on the daily chart. …

Ally Financial (NYSE: ALLY) CRO trades 5,000 shares in 10b5-1 sale

Ally Financial's Chief Risk Officer, Stephanie N. Richard, sold 5,000 shares of common stock on August 4, 2026, at a weighted average price of $44.2336 per share. This sale was conducted under a Rule 10b5-1 trading plan adopted in January 2026. Following the transaction, …

O'Reilly Auto Parts Is Paying $18.8 Million Because Its Texts Wouldn't Take No for an Answer

O'Reilly Auto Parts Is Paying $18.8 Million Because Its Texts Wouldn't Take No for an Answer Every gearhead who's ever handed over a phone number at the parts counter for a rewards discount knows the tradeoff: a few bucks off a battery today, and …

Eli Lilly and Co Stock (LLY) Moved Up by 6.32% on Aug 5: A Full Analysis

Eli Lilly and Co (LLY) stock rose by 6.32% on August 5th, driven by strong quarterly earnings that surpassed expectations and increased full-year financial guidance. The company's metabolic health portfolio performed exceptionally well, supported by expanding clinical applications for its drugs and improved manufacturing …

Eli Lilly stock soars on strong demand for weight loss drugs

What happened: Eli Lilly (LLY) stock jumped as much as 7% on Wednesday. What's behind the move: The drug company raised its 2026 sales forecast after it saw strong demand for GLP-1 drugs in its fiscal second quarter. Revenue is now expected to fall …

Eli Lilly Stock Rises as Volume Growth Outruns Falling Prices

This article first appeared on GuruFocus. Eli Lilly and Company (NYSE:LLY) rose 5.12% in premarket trading after posting second-quarter revenue of $22.97 billion, up 48% and well clear of the $20.69 billion analyst estimate. Non-GAAP earnings landed at $8.38 a share against a $6.01 …

ALLY5680208 Bond Risk Profile

This page provides a risk profile for the ALLY5680208 bond issued by Ally Financial Inc., featuring a 7.6% interest rate and maturing on November 15, 2028. It highlights key metrics for credit risk assessment, including security level and issuer rating, to help investors evaluate …

Eli Lilly's Weight-Loss Engine Is Still Accelerating

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind several leading diabetes and obesity treatments, reported second-quarter earnings and revenue well above Wall Street estimates as demand for Zepbound and Mounjaro continued to surge. Warning! GuruFocus has …

Eli Lilly's Diabetes And Obesity Drugs Blow Past Expectations; Shares Pop

Eli Lilly stock jumped Wednesday on a solid beat-and-raise thanks to its GLP-1 drugs, treatments for diabetes and obesity. Continue Reading

Mounjaro sales double this year as obesity drug boom prevails, says maker

Worldwide sales of weight loss and diabetes jab Mounjaro have doubled this year as demand continues to boom, drugmaker Eli Lilly has revealed. The manufacturer said its obesity medications Mounjaro and Zepbound were driving an acceleration of its overall sales. Mounjaro sales totalled 18.6 …

Rumoured GPC–O’Reilly deal refuted, but still revealed much

A rumored US$10 billion acquisition of Genuine Parts Company's automotive business by O’Reilly Automotive has been firmly denied by both companies. The speculation, initially reported by Bloomberg, caused GPC shares to jump and O’Reilly stock to slip. Despite the refutation, the event highlighted the …

Eli Lilly (LLY) Q2 Earnings and Revenues Surpass Estimates

Eli Lilly (LLY) came out with quarterly earnings of $8.38 per share, beating the Zacks Consensus Estimate of $6.01 per share. This compares to earnings of $6.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth

Eli Lilly has raised its full-year revenue forecast after reporting better-than-expected quarterly results, driven by strong demand for its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound. The company's shares rose 5% in premarket trading, reassuring investors about its market position despite increasing competition …

Eli Lilly and Company aktualisiert Ergebnisprognose für das Jahr 2026

CVS Health Stock Climbs on Earnings Outlook Hike and Lilly Weight-Loss Drug Partnership

CVS Health stock jumped on Wednesday after the healthcare giant raised its full-year guidance on the back of second-quarter earnings that handily beat analysts’ projections. For the second quarter, CVS Health posted adjusted earnings of $2.58 a share. Analysts polled by FactSet were looking …

Lilly’s obesity pill Foundayo ‘disappointed’ in Q2, as injectables continue to boom

Eli Lilly's new oral GLP-1 treatment, Foundayo, reported Q2 sales of $98 million, significantly trailing Novo Nordisk's rival Wegovy pill. Despite this, positive trends for Foundayo in the U.S. and strong international potential were noted. Meanwhile, Lilly's injectable diabetes and obesity medicines, Mounjaro and …

Lilly Stock Jumps on Earnings Beat as Mounjaro Revenue Nearly Doubles

Eli Lilly posted a blockbuster second quarter fueled by continued demand for its portfolio of GLP-1 medications. The world’s biggest drugmaker by market value reported adjusted earnings of $8.38 a share in the period, better than the $6.01 consensus estimate among analysts polled by …

Eli Lilly shares pop as weight-loss drug demand fuels guidance hike

Investing.com -- Eli Lilly shares jumped more than 5% in premarket trading Wednesday after the U.S. pharma giant raised its annual revenue guidance amid strong demand for its popular weight-loss and diabetes drugs. The company lifted its full-year 2026 revenue guidance to $85 billion …

Hollywood Bowl (LSE:BOWL) Makes Consumer Resilience Live Small-Cap Question

Sally Beauty CEO and CFO to Present Aug. 11 in Boston

Sally Beauty Holdings, Inc. announced that its President and CEO, Denise Paulonis, and CFO, Adrianne Lee, will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026, at 10:00 AM ET. The presentation will be webcast live on the …

Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Eli Lilly significantly surpassed its second-quarter earnings and revenue estimates, prompting an increase in its full-year sales forecast. This strong performance was primarily driven by the surging demand for its weight-loss drug Zepbound and diabetes treatment Mounjaro. The company also reported initial sales from …

CVS and Lilly plan same-day Zepbound pickup by early Q4

CVS Health is expanding its direct-to-consumer weight management offerings, focusing on GLP-1 medications, by combining digital care and in-store support. A new collaboration with Eli Lilly will enable eligible Zepbound and Foundayo patients to view transparent pricing in the CVS Health app for potential …

Eli Lilly shares rise on revenue beat, raised outlook

Eli Lilly's shares rose nearly 7% after the drugmaker reported second-quarter revenues of $22.97 billion, exceeding Wall Street expectations, and raised its full-year 2026 revenue outlook to $85 billion to $87 billion. The strong performance was primarily driven by robust demand and sales increases …

Wise Ally International Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2026